Inherited mutations of the BRCA2 gene give rise to a multi-site cancer phenotype which includes breast cancer (in female and males), ovarian, pancreatic and prostate cancer, ocular and other melanomas, laryngeal, colon and stomach cancers. Interpretation of test results and risk assessment is therefore complex. It has been proposed that families with mutations in the ovarian cancer cluster region (OCCR) of exon 11 (nucleotides 3035-6629) express a higher ratio of ovarian to breast cancer, than families with mutations elsewhere in the BRCA2 gene. In this study we have investigated the presence of 7 types of cancer (ovary, male breast, pancreas, prostate, colon, stomach and melanoma) in first-and second-degree relatives of mutation-positive individuals in 440 families with a BRCA2 mutation. We reviewed histories of cancer in relatives among families with mutations distributed throughout the gene. Families with ovarian cancer were more likely to harbour mutations in the OCCR (nucleotides 3035-6629) than elsewhere in the gene (OR = 2.21; P = 0.0002). We also compared cancer risks according to ethnic group. Ashkenazi Jewish families with the 6174delT founder mutation were more likely to have a family member with ovarian cancer (OR = 1.58; P = 0.002) and less likely to have a family member with prostate cancer (OR = 0.62; P = 0.04) than were non-Jewish families. In contrast, a reduced presence of ovarian cancer was found in families of French-Canadian ancestry, compared to other ancestries (OR = 0.37; P = 0.0026). A high risk of male breast cancer was observed with the 6503delTT mutation (OR = 15.7; P = 0.023). Families of Polish ancestry had a reduced frequency of pancreatic cancer (OR = 0.0; P = 0.03) compared to families of other ethnic origins. In conclusion, both the position of mutation and the ethnic background of the family appear to contribute to the phenotypic variation observed in families with BRCA2 mutations.
Introduction
The BRCA2 gene was mapped to chromosome 13q21 in 1994 [1] and was identified in 1995 [2, 3] .
Subsequently, BRCA2 mutations have been identified in numerous hereditary breast cancer families. The majority are frameshift mutations and are caused by small deletions or insertions (Breast Cancer Information Core (BIC) database) but nonsense mutations are also observed. To date it has not been proven that missense mutations in BRCA2 (which lead to single amino acid substitutions) are deleterious. Inherited mutations of the BRCA2 gene give rise to a variable cancer phenotype including female breast and ovarian cancer, male breast, pancreatic and prostate cancer, ocular and other melanomas, laryngeal, colon, stomach, gallbladder and bile duct cancers [4] . The risk is high for men as well as for women; in one study it was reported that when cancers at all sites were included, the lifetime penetrance for the development of cancer for a BRCA2 mutation for males (53%) exceeded that for females (38%) [5] . The knowledge that a particular mutation may increase the risk of a specific cancer will be of interest to members of the clinical genetics and oncology communities involved in hereditary cancer risk assessment. At-risk individuals might benefit from clinical screening for a wide spectrum of cancers.
A relatively high ratio of ovarian cancers to breast cancers was initially reported in a small study of 27 families with mutations in a 3.3 kb segment of exon 11 of BRCA2, spanned by nucleotides 3035 and 6629. Gayther et al. termed this the 'ovarian cancer cluster region' or OCCR. More recently, Thompson et al. suggested that the boundaries of the OCCR region might be narrowed slightly -the 5 ′ boundary was mapped to the interval between nucleotides 3059-4075 and the 3′ boundary was mapped to the interval between nucleotides 6503-6629 [7] . The relative risks for ovarian cancer (RR = 1.88), breast cancer (RR = 0.63) and prostate cancer (RR = 0.53) differed significantly for carriers with mutations within this region, compared to carriers with mutations in the remainder of the gene [7] . It appears therefore, that the high ratio of ovarian cancers to breast cancers in families with mutations in the OCCR is attributable to both a relatively high risk of ovarian cancer and a relatively low risk of breast cancer.
Our aim in this study was to investigate the clinical expression of mutations distributed throughout the BRCA2 gene with reference to seven different cancer types in a large collection of 440 families with BRCA2 mutations. Such data may be clinically useful in providing cancer risks to individuals harbouring BRCA2 mutations.
Materials and methods

Materials
The 440 families included in this study were selected on the basis of one or more individuals carrying a BRCA2 mutation. Pedigrees have been collected at participating research centers in Canada, the USA and Poland as part of other clinical and research protocols. The testing criteria for the families varied by center, but reports of cancers at sites other than breast or ovary were not used to determine eligibility for testing. A variety of methods was used to identify BRCA2 mutations, including the protein truncation test (PTT), flourescence-tagged single-strand conformation polymorphism analysis (fSSCP), denaturing gradient gel electrophoresis (DGGE), multiplex PCR for the 3 Ashkenazi Jewish founder mutations (of which BRCA2 6174delT is relevant here), multiplex PCR for the French-Canadian founder mutations (of which BRCA2 G6085T, 6503delTT and 8765delAG mutations are relevant here) and direct DNA sequencing.
The pedigree information was collated and prepared for statistical analysis at the Center for Research in Women's Health, Toronto, Canada. For each of the seven cancer types, each family was assigned to one of two categories, depending on the presence of at least one cancer of a specific type in a first-or second-degree relative of a mutation carrier in the family, or in the tested individual him/herself.
Statistical analysis
SAS version 8.1 statistical package was employed for all analyses. Fishers' exact test was used to assess statistical significance of the odds ratios. All statistical tests were two-sided.
Results
The 440 families with known BRCA2 mutations were assessed for each of 7 cancer types (ovarian, pancreatic, prostate, male breast, colon, stomach and melanoma). The ethnic distribution of the 440 families is presented in Table 1 . Overall there were 140 different mutations, of which 49 were recurrent; i.e., each occurred in two or more families. The most common mutation was the 054  British  044  German  026  Polish  026  Irish  016  Italian  017  Other White  013  Scottish  007  Filipino  005  Icelandic  004  Japanese  004  African American  003  Dutch  003  Danish  002  Hispanic  002  Greek  001  Indian  001  Iranian  001 6174delT Ashkenazi founder mutation (159 families) followed by the French-Canadian founder mutation 8765delAG (27 families). The mutations and their locations are given in Figure 1 , where the odds ratio for the presence of ovarian cancer in the family, for mutations within in each 1 kb interval spanning the entire BRCA2 gene is presented. The odds ratios were below unity until approximately nucleotide 3500; were above unity Cancers associated with BRCA2 gene mutations 3 from nucleotide 3500 to 7400, and again fell below unity for nucleotides 7400 and beyond. As in previous studies, the present analysis suggests that the OCCR does not include all of exon 11. There were 17 families with mutations in the 2157-3034 region of exon 11; i.e., 5′ to the originally defined OCCR (3035-6629). The presence of ovarian cancer was significantly less for families with mutations in this region, compared to families with mutations elsewhere in BRCA2 (OR = 0.26; P = 0.025) or in exon 11 (OR = 0.20; P = 0.007). Therefore, this study supports the original assignment of Gayther et al. of the 5′ border of the OCCR to be at position 3035 [6] .
Originally, the 3′ border of the OCCR was defined as nucleotide 6629, near the 3′ boundary of exon 11. Thompson et al. propose that the 3′ border of the OCCR is located in the region 6503-6629 [7] . Among the 14 families with mutations in this small interval there was neither an excess nor deficit of ovarian cancer (OR = 1.06; P = 1.0), therefore data are insufficient data to support a reassignment of this boundary.
In summary, this data supports the original assignment of the OCCR as encompassing nucleotides 3035 to 6629. The odds ratio for ovarian cancer being present in families with OCCR mutations, compared to non-OCCR mutations was 2.21 (P = 0.0002) ( Table 3 ).
The presence of the other 6 types of cancer was determined for mutations in each of the six contiguous segments (A-F) of BRCA2, compared to mutations in the remainder of the gene. We did not confirm the observation of Thompson et al. that OCCR mutations were associated with a diminished risk of prostate cancer, although the observed association was in the right direction (OR = 0.84; P = 0.43) [7] . None of the other associations were significant. For no cancer type other than ovary was there a significant excess risk associated with the OCCR (Table 3) .
The distribution of cancer in the families was also examined by ethnic group. There were 159 families with the 6174delT mutation in this study. Of these, 154 were reported to be Ashkenazi (or of unspecified Jewish) descent, 3 families were Polish (non-Jewish) and for 2 families ethnicity was not available. The 6174delT mutation is located within the OCCR. The risks associated with the seven cancer types were analysed for the 6174delT mutation compared to all other mutations combined (Table 4 ). An increased risk of ovarian cancer (OR = 1.58; P = 0.02) and a decreased risk of prostate cancer (OR = 0.62; P = 0.04) were found to be associated with the BRCA2 6174delT mutation. The association of the OCCR and ovarian cancer was not solely attributable to the 6174delT mutation. Among the other Cancers associated with BRCA2 gene mutations 5 136 families with mutations in the OCCR, 6174delT excluded, the odds ratio for ovarian cancer was 2.18 (P = 0.002), compared to families with mutations elsewhere in the gene. There were 54 families of French-Canadian descent. The risks were determined for the 7 cancer types in the 54 French-Canadian families compared to the remaining 386 families (Table 5 ). The presence of ovarian cancer was decreased in French-Canadian families, compared to other families (OR = 0.39, P = 0.003). There was no effect observed for the other six cancer types (Table 5) . Among the French-Canadian families, those with a 6503delTT mutation had a higher prevalence of male breast cancer than other French-Canadian families (OR = 15.7; P = 0.023).
There were 28 families of Polish descent in the study, with BRCA2 mutations distributed throughout the gene. The Polish families showed a reduced frequency of pancreatic cancer (OR = 0.0; P = 0.03), and of colon cancer (OR = 0.25; P = 0.056) (although of borderline significance) as compared to families of other ethnic groups (Table 6 ).
Discussion
The results of our study of 440 families with 140 distinct BRCA2 mutations support the assignment of the OCCR to the region spanned by nucleotides 3035 and 6629. Families with mutations located within this interval were approximately twice as likely to contain women affected with ovarian cancer as families with other mutations (OR = 2.21; P = 0.0002). A relatively low risk of ovarian cancer was observed for families with mutations in the region of exon 11 encompassing nucleotides 2157-3034 (OR = 0.26; P = 0.025). This observation supports the prior assignment of the 5′ border of the OCCR to nucleotide 3035. However, precise assignment of the 3′ boundary of the OCCR is difficult. The risk of ovarian cancer associated with mutations in the region 6503-6619 was similar to that for other mutations (OR = 1.06; P = 1.00). The assignment of the 3′ boundary of the OCCR to 6619 is somewhat arbitrary because there were relatively few families with mutations in this region. The transition in risk in the 3′ boundary of the OCCR was gradual, in contrast to the 5′ region for which the transition was relatively abrupt (Figure 1) . This study provides compelling evidence that the risk of ovarian cancer in all BRCA2 families is not uniform -but it is nevertheless difficult to generate precise estimates of risk for individuals based on the position of the mutation in the family. There are several limitation to our study which preclude a definitive analysis. The cancers documented in the families were based on proband interviews and the majority of reported cancers were not confirmed. It is possible that some cancers were missed and others were misassigned. Ideally, we are interested in only those cancers in BRCA2 carrier relatives, and it is expected that only one-half of the first-degree relatives will carry the mutation that is identified in the proband. We did not know the mutation status for the affected relatives. Families were classified into those with and without a cancer of a particular site. To the extent that family sizes vary and differences in the diligence applied in obtaining pedigree details, the probability of ascertaining cancers in relatives will vary. The entry criteria for testing families for BRCA2 mutations may vary from center to center. This will create a problem if a cancer of interest is used as a criteria for testing at one center but not at another. However, it is unlikely that cancers other than of the breast and ovary were used in pedigree ascertainment and testing decisions. Rates of prostate cancer are highly dependent on screening practices and the observed variation in rates between families and between countries may reflect differences in the utilization of screening. For other sites, such as ovary and pancreas, screening is less of a concern. Finally, multiple comparisons were made and many of the associations reported here are consistent with chance variation. The ideal study would be to follow prospectively a large cohort of healthy BRCA2 carriers for all incident cases of cancer. However, in order to generate accurate risk estimates for individual cancer types and for different classes of mutations it would be necessary to follow several thousand mutation carriers for an extended period of time.
Ultimately, it is hoped that knowledge of genotype/ phenotype correlations will allow genetic counselors to provide mutation-specific risk estimates for the different forms of cancer. With the exception of ovarian cancer, the data is not yet sufficiently strong to reject the prior hypothesis that the risk is uniform across the gene, and it is important that our observations be extended. In the case of ovarian cancer, it appears that mutations in the 3′ portion of exon 11 confer the highest risk of ovarian Cancers associated with BRCA2 gene mutations 7 cancer. We also saw an increase in ovarian cancer risk with mutations in the 3′ region of the gene, encompassing exons 23-26 ( Figure 1 ) but this peak was based on a small number of families and did not reach statistical significance. The present study does not permit us to estimate lifetime penetrance rates of ovarian cancer for women with BRCA2 mutations. Knowledge of age-specific ovarian cancer risks would be useful for women and their physicians in making decisions regarding preventive oophorectomy. Oral contraceptives are an attractive option for BRCA2 carriers as they have been shown to diminish the risk of ovarian cancer [8], and appear not to increase the risk of breast cancer [9] . Therefore it is reasonable to offer an oral contraceptive to BRCA2 carriers at all levels of risk.
This study is the first to consider the variation in cancer risk among BRCA2 carriers associated with the different ethnic groups. Because the distribution of mutations differs among different ethnic groups (primarily due to the presence of common founder mutations) it is difficult to distinguish the effects of the mutation from that of the ethnic group. For example, Jewish women with the 6174delT mutation comprised 35% of all families studied. There were no Jewish women with other mutations and only three women with the 6174delT mutations reported themselves to be nonJewish. Therefore it is not possible to distinguish the effect of Jewish ancestry from that of the specific 6174delT mutation.
Our data suggests the possibility of a colon cancer (OR = 3.57; P = 0.0072) and stomach cancer (OR = 2.82; P = 0.043) cluster region bounded by nucleotides 3059-4075, but this needs to be confirmed. The observed differences in cancer rates in BRCA2 carriers may reflect local cancer incidence rates [10] . This difference appears to be present among BRCA2 carriers as well. Jakubowska et al. previously noted a high incidence of stomach cancers in Polish families with BRCA2 mutations [11] . The relative risk for stomach cancer among BRCA2 carriers compared to non-carriers has been estimated to be 2.6 [4].
The cumulative risk of developing male breast cancer by age 80 years in a BRCA2 carrier has been estimated to be 7% [7] . We found evidence of male breast cancer risk being significantly greater than expected for French-Canadian families with the 6503delTT mutation (OR = 15.7; P = 0.02); however, this observation was based on a few families. French-Canadian families were found to have fewer ovarian cancers compared to other families (OR = 0.37; P = 0.003). It appears that ovarian cancer risk is dependent on both ethnic background and 8 J. Lubinski et al. Pancreatic cancer is the fourth leading cause of death due to cancer for both males and females in the USA and cases of pancreatic cancer have been observed in breast-ovarian cancer families with BRCA2 mutations [12, 13] . The Breast Cancer Linkage Consortium estimates the relative risk for pancreatic cancer among BRCA2 carriers to be 3.5 [4] . Fifty-eight families in this study had at least one case of pancreatic cancer, but we saw no evidence that the position of the mutation in the gene has an influence on pancreatic cancer risk. However, there was no pancreatic cancer in the 28 Polish families in this study, whose mutations were distributed throughout the gene. Melanomas have also been observed in breast-ovarian cancer families with mutations in BRCA2. The relative risk for developing malignant melanoma has been estimated to be 2.6 [4]. In particular, ocular melanomas have been observed at a higher frequency than expected in BRCA2 carriers [14, 15] . In our study, 31 of 440 families reported melanoma, but there was no evidence that the position of the BRCA2 mutation influenced melanoma risk.
The biological explanation for the variation in risk is unclear. BRCA2 functions in the maintenance of genomic stability and in the repair of double-strand DNA breaks [16] [17] [18] . Interestingly, the OCCR is coded for by the large exon 11 and overlaps with the region of exon 11 which contains 8 BRC repeat units. These repeats are globular structural motifs that mediate binding to RAD51, the human homolog of bacterial RecA. RAD51 is involved in directing strand invasion during recombination [19] [20] [21] . BRCA2 regulates RAD51 function by controlling its intracellular localization and by modulating its ability to form nucleofilaments. The latter function is mediated by two of the BRC repeats, BRC3 and BRC4 [22] [23] [24] [25] . Located 5′ of the BRC repeats is a region which shares high identity with other BRCA2 orthologues (and is likely to be functionally important) [26] . This region interacts with DSS1 and is able to bind single-stranded DNA [26] [27] . The carboxy-terminal region of BRCA2 also includes the nuclear localization signals (NLS) [28] .
Assuming that premature truncated proteins are generated and are stable, we might speculate that the loss of the RAD51-and DSS1-binding regions, alone or in combination, might explain the observed variation in ovarian cancer risk. The data in Figure 1 show a drop in the odds ratio that coincides with the loss of the DSS1-interacting region. Partial length transcripts which contain this region will invariably disrupt the DSS1-interacting region and the NLS but will retain the RAD51-binding region. Similarly, mutations which retain all but the N-terminal region are associated with a low risk of ovarian cancer. The increase in ovarian cancer risk coincides with the retention of the BRC repeat clusters. Mutations in the N-terminal region will result in proteins which have lost all the known structural domains of BRCA2 (NLS, RAD51-and DSS1-interacting region). Conversely, mutations in the region presenting the highest risk of ovarian cancer are expected to disrupt the DSS1-interacting region and the NLS, but still retain some or all BRC repeats.
The inspection of the BRCA2 functional domains does not help to explain why the regions of high risk for ovary and breast cancer should be different. One possibility is that different mutations have different effects on the apoptosis response in the breast and ovary. Conceivably, a mutation could trigger early apoptosis in the ovary but not in the breast and therefore the breast cells could progress through tumorigenesis. An independent line of research suggests that mutations that lead to transcripts which retain the RAD51-binding region generate a less severe phenotype than mutations located in the 5′ region of the protein. Recently, it was shown that some patients with Fanconi anemia carry biallelic inactivation of BRCA2. Germline biallelic inactivation of BRCA2 had previously been considered to be embryonic lethal suggesting that the mutations associated with Fanconi anemia have a less severe clinical expression. Fanconi anemia patients carrying mutations in BRCA2 have either both or at least one allele with truncations located 3′ to exon 11 [29] . Individuals with truncating mutations in exon 27 and which lead to the loss of the terminal portion of the BRCA2 gene seem to have no functional consequence in the heterozygous state [30] but the possibility of a homozygote effect has not been excluded.
Alternatively, differences in risk could be explained by differential mRNA degradation mediated by the nonsense-mediated decay (NMD) pathway. It has been proposed that NMD is triggered by premature termination codons (PTC) which are situated close to an exon-exon junction. Interestingly, it has been shown that PTC located more than 559 nucleotides 5′ to the exon-exon junction escaped NMD detection [31] . In this case mutations in the large exon 11 of BRCA2 would have a higher chance of escaping NMD-mediated degradation than mutations in the small exons, which are all in the vicinity of an exon-exon boundary. Mutations in the OCCR would therefore be more likely to lead to the production of a protein product than mutations elsewhere in the gene. However, a recent study on PTC in BRCA1, which also contains a large exon 11, showed that PTC located farther than 559 nucleotides from an exon-exon boundary were still subject to NMD [32] . It remains to be seen if this is also the case for BRCA2.
Conclusions
In conclusion, the risk of ovarian cancer among carriers of BRCA2 mutations varies according to the position of mutation in gene. Additional factors which modify cancer risk include country of origin, which may in turn Cancers associated with BRCA2 gene mutationsreflect differences in ethnic background and in environmental and lifestyle risk factors. The biological basis for the differences in cancer risk remain to be explored. It is not yet possible to offer specific ovarian cancer risk estimates to patients with different mutations in the clinical setting.
